Show simple item record

dc.contributor.authorDhillon, KKen_US
dc.contributor.authorBajrami, Ien_US
dc.contributor.authorTaniguchi, Ten_US
dc.contributor.authorLord, CJen_US
dc.date.accessioned2017-03-06T15:49:18Z
dc.date.issued2016-10en_US
dc.identifier.citationEndocrine-related cancer, 2016, 23 (10), pp. T39 - T55en_US
dc.identifier.issn1351-0088en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/475
dc.identifier.eissn1479-6821en_US
dc.identifier.doi10.1530/erc-16-0228en_US
dc.description.abstractWhen the BRCA1 and BRCA2 tumour suppressor genes were identified in the early 1990s, the immediate implications of mapping, cloning and delineating the sequence of these genes were that individuals in families with a BRCA gene mutation could be tested for the presence of a mutation and their risk of developing cancer could be predicted. Over time though, the discovery of BRCA1 and BRCA2 has had a much greater influence than many might have imagined. In this review, we discuss how the discovery of BRCA1 and BRCA2 has not only provided an understanding of the molecular processes that drive tumourigenesis but also reignited an interest in therapeutically exploiting loss-of-function alterations in tumour suppressor genes.en_US
dc.formatPrint-Electronicen_US
dc.format.extentT39 - T55en_US
dc.languageengen_US
dc.language.isoengen_US
dc.titleSynthetic lethality: the road to novel therapies for breast cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-08-15en_US
rioxxterms.versionofrecord10.1530/erc-16-0228en_US
rioxxterms.licenseref.startdate2016-10en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEndocrine-related canceren_US
pubs.issue10en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Gene Function
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gene Function
pubs.volume23en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamGene Functionen_US
dc.contributor.icrauthorLord, Christopheren_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record